Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02243007
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:34.527977+00:00
Published At
2017-05-16T00:00:00+00:00
Record Updated At
2017-05-16
Results Posted At
2017-05-16
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Resectable Pancreatic Cancer", "Pancreatic Ductal Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2017-05-16"
protocolSection.identificationModule.nctId
"NCT02243007"
protocolSection.identificationModule.officialTitle
"Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2017-05-16"

Study condition terms

  • Resectable Pancreatic Cancer (protocolSection.conditionsModule.conditions)
  • Pancreatic Ductal Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.